Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Tislelizumab × sintilimab × Gastrointestinal × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 48 Stomach Neoplasms 39 Colorectal Neoplasms 19 Esophageal Squamous Cell Carcinoma 16 Rectal Neoplasms 9 Esophageal Neoplasms 8 Pancreatic Neoplasms 7 Cholangiocarcinoma 6 Liver Neoplasms 5 Colorectal Cancer Metastatic 3 Colonic Neoplasms 3 Neoplasms 2 Locally Advanced Rectal Cancer 2 Gastric Adenocarcinoma 2 Advanced Biliary Tract Cancer 2 Uterine Cervical Neoplasms 1 Turcot syndrome 1 Tislelizumab 1 Recurrence 1 Pancreatic Cancer Resectable 1 Pancreatic Cancer Metastatic 1 PD-1 Antibody 1 Ovarian Neoplasms 1 Neoplasms, Squamous Cell 1 Neoplasm Metastasis 1 Microsatellite Stable Metastatic Colorectal Cancer 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1 Metastasis Colorectal Cancer 1 Locally Recurrent Rectal Cancer 1 Locally Advanced Rectal Cancer (LARC) 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡